Myriad Genetics, Inc. (MYGN) Tops Q3 EPS by 3c; Boosts FY14 Outlook

Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q3 EPS of $0.48, $0.03 better than the analyst estimate of $0.45. Revenue for the quarter came in at $176.2 million versus the consensus estimate of $175.23 million.

Myriad Genetics, Inc. sees FY2014 EPS of $2.37 - $2.40, versus prior guidance of $2.09 - $2.12 and the consensus of $2.19. Myriad Genetics, Inc. sees FY2014 revenue of $770 - $775 million, versus prior guidance of $740 - $750 million and the consensus of $764.01 million.

For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c